Targeted therapy vs. chemotherapy for thyroid cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares a targeted therapy pill combination (dabrafenib and trametinib) with cabozantinib or chemotherapy for people with a specific type of advanced thyroid cancer (differentiated thyroid cancer) that has a BRAF V600E mutation. It aims to find which treatment works better after previous treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of thyroid cancer called differentiated thyroid cancer, which includes papillary or follicular types, and test positive for the BRAF V600E gene change.
- You must have already tried a type of targeted therapy called a VEGFR inhibitor (such as lenvatinib or sorafenib), and your cancer must have continued to grow.
- You must have had radioactive iodine treatment or be unable to have it, and you must be on thyroid hormone suppression therapy.
- You must have measurable cancer on a CT or MRI scan done within the last 4 weeks.
- You must not have had certain types of prior treatments (like cabozantinib or BRAF inhibitors) or have serious heart, bleeding, or stomach problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
This trial tests a new way to choose chemotherapy for thyroid cancer by growing a 'mini-tumor' (organoid) from your biopsy and testing different drugs on it. The goal is to find the drug that is most likely to shrink your cancer.
Hear when a new Refractory Differentiated Thyroid Gland Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.